Amyotrophic lateral sclerosis therapy with non-purine analog xanthine oxidoreductase inhibitors
Project/Area Number |
24500420
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Nerve anatomy/Neuropathology
|
Research Institution | Tottori University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
KATO Masako 鳥取大学, 医学部, 助教 (80221183)
TAKIKAWA Miki 鳥取大学, 医学部, 助教 (80724369)
YOKOYAMA Atsushi 鳥取大学, 医学部, 助教 (90529447)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 神経変性疾患 / 筋萎縮性側索硬化症 / 経口治療薬 / キサンチン酸化還元酵素 / キサンチン酸化還元酵素阻害剤 / プリン非類似体 / アロプリノール / プリン体 |
Outline of Final Research Achievements |
The aim of this study is to develop the new therapeutic drug for amyotrophic lateral sclerosis (ALS) that is one of the intractable diseases in which there is not an effective therapy now. Non-purine analog xanthine oxidoreductase (XOR) inhibitors as the newly-developed therapeutic drug for ALS were administered orally into the ALS model mice. The results of this study were as follows: the treated ALS mice were significantly survived, and significantly improved ALS symptoms in comparison with the untreated ALS mice. Histopathologically, the treated ALS mice were well-preserved in motor neurons, compared with the untreated ALS mice. These results show that the non-purine analog XOR inhibitors are candidates for the human ALS therapeutic drug.
|
Report
(4 results)
Research Products
(42 results)
-
-
-
[Journal Article] High viral load of Merkel cell polyomavirus DNA sequences in Langerhans cell sarcoma tissues.2014
Author(s)
Murakami I, Matsushita M, Iwasaki T, Kuwamoto S, Kato M, Horie Y, Hayashi K, Gogusev J, Jaubert F, Nakamoto S, Yamakawa M, Nakamine H, Takata K, Oka T, Yoshino T.
-
Journal Title
Infect Agent Cancer
Volume: 9
Issue: 1
Pages: 15-15
DOI
Related Report
Peer Reviewed / Open Access
-
-
[Journal Article] Presence of Epstein-Barr virus-infected B lymphocytes with thyrotropin receptor antibodies on their surface in Graves' disease patients and in healthy individuals2014
Author(s)
Nagata K, Higaki K, Nakayama Y, Miyauchi H, Kiritani Y, Kanai K, Matsushita M, Iwasaki T, Sugihara H, Kuwamoto S, Kato M, Murakami I, Nanba E, Kimura H, Hayashi K.
-
Journal Title
Autoimmunity
Volume: 47
Pages: 193-200
Related Report
Peer Reviewed
-
-
-
-
-
-
[Journal Article] EBNA-2 -deleted Epstein-Barr virus from P3HR-1 can infect rabbits with lower efficiency than prototype Epstein-Barr virus from B95-8.2013
Author(s)
Sano H, Nagata K, Kato K, Kanai K, Yamamoto K, Okuno K, Kuwamoto S, Higaki-Mori H, Sugihara H,Kato M, Murakami I, Kanzaki S, Hayashi K.
-
Journal Title
Intervirology
Volume: 56
Issue: 2
Pages: 114-21
DOI
Related Report
Peer Reviewed
-
[Journal Article] IL-17A receptor expression differs between subclasses of Langerhans cell histiocytosis, which might settle the IL-17A controversy.2013
Author(s)
Murakami I, Morimoto A, Oka T, Kuwamoto S, Kato M, Horie Y, Hayashi K, Gogusev J, Jaubert F, Imashuku S, Al-Kadar LA, Takata K, Yoshino T.
-
Journal Title
Virchows Arch
Volume: 462
Issue: 2
Pages: 219-228
DOI
Related Report
Peer Reviewed
-
-
-
[Journal Article] FUS/TLS-immunoreactive neuronal and glial cell inclusions increase during in the disease progression of FALS with an R521C FUS/TLS mutation.2012
Author(s)
Suzuki N, Kato S, Kato M, Warita H, Mizuno H, Kato M, Shimakura N, Akiyama H, Kobayashi Z, Konno H, Aoki M
-
Journal Title
J Neuropathol Exp Neurol
Volume: 71
Issue: 9
Pages: 779-788
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Prognostic significance of sirtuin 2 protein nuclear localization in glioma: an immunohistochemical study2012
Author(s)
Imaoka N, Hiratsuka M, Osaki M, Kamitani H, Kambe A, Fukuoka J, Kurimoto M, Nagai S, Okada F, Watanabe T, Ohama E, Kato S, Oshimura M
-
Journal Title
Oncol. Rep
Volume: 28
Issue: 3
Pages: 923-930
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-